SAN DIEGO, March 14, 2017 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced the appointment of Alexey Vinogradov, Ph.D., to its board of directors. Dr. Vinogradov currently serves as Head of Pharmstandard Ventures, a corporate venture fund of Pharmstandard Group, until recently known as Inbio Ventures, where he served as a Managing Partner and CEO. Dr. Vinogradov replaces Dr. Andrei Petrov as a director of the company.
"We are excited to have Alexey join our board during this exciting time of Avelas' corporate development," said Carmine Stengone, president and CEO of Avelas Biosciences. "Alexey has considerable experience in research and development, operations and business development, and I'm confident he will contribute meaningfully to our future success."
Dr. Vinogradov has over 15 years of experience at different positions in the biotech industry. He has served as a board member at Argos Therapeutics, as a board observer at Protagonist Therapeutics and Aquinox, and currently serves as a board observer at Allena Pharmaceuticals. Prior to joining Inbio Ventures in 2012, as co-founding partner and CBO, Dr. Vinogradov was involved in portfolio building at Bioprocess Capital Partners. He also led the fundraising and served in the executive management of Promogene, Tartis-Oncology and Everon. In addition, Dr. Vinogradov was involved in a range of business development activities at Bioprocess Group.
Dr. Vinogradov held a postdoctoral position at the Laboratory of Biomolecular Sciences, Wageningen University, Netherlands. He obtained his Ph.D. degree in Biochemistry and MS degree in Chemistry from Moscow State University.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. The initiation of a Phase 2 clinical trial for AVB-620 in breast cancer is expected in the first half of 2017. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded by Avalon Ventures on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.
Advertisement
"We are excited to have Alexey join our board during this exciting time of Avelas' corporate development," said Carmine Stengone, president and CEO of Avelas Biosciences. "Alexey has considerable experience in research and development, operations and business development, and I'm confident he will contribute meaningfully to our future success."
Advertisement
Dr. Vinogradov has over 15 years of experience at different positions in the biotech industry. He has served as a board member at Argos Therapeutics, as a board observer at Protagonist Therapeutics and Aquinox, and currently serves as a board observer at Allena Pharmaceuticals. Prior to joining Inbio Ventures in 2012, as co-founding partner and CBO, Dr. Vinogradov was involved in portfolio building at Bioprocess Capital Partners. He also led the fundraising and served in the executive management of Promogene, Tartis-Oncology and Everon. In addition, Dr. Vinogradov was involved in a range of business development activities at Bioprocess Group.
Dr. Vinogradov held a postdoctoral position at the Laboratory of Biomolecular Sciences, Wageningen University, Netherlands. He obtained his Ph.D. degree in Biochemistry and MS degree in Chemistry from Moscow State University.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. The initiation of a Phase 2 clinical trial for AVB-620 in breast cancer is expected in the first half of 2017. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded by Avalon Ventures on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avelas-biosciences-appoints-alexey-vinogradov-phd-to-board-of-directors-300423042.html
SOURCE Avelas Biosciences, Inc.
